<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2019-1-82-89</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-618</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФАРКТ МИОКАРДА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MYOCARDIAL INFARCTION</subject></subj-group></article-categories><title-group><article-title>Оценка оптимального уровня холестерина липопротеинов высокой плотности в когорте мужчин 40-59 лет, перенесших инфаркт миокарда (по данным 30-летнего мониторинга статуса жизни пациентов)</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of the optimal values of cholesterol of high density lipoproteins in a cohort of men aged 40-59 with myocardial infarction (according to 30-year monitoring of the status of life)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белов Вячеслав Владимирович — доктор медицинских наук, профессор кафедры госпитальной терапии,</p><p>Челябинск</p></bio><bio xml:lang="en"/><email xlink:type="simple">md-belov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5801-5083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меньщиков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Menshchikov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Меньщиков Анатолий Алексеевич— кандидат медицинских наук, заслуженный врач РФ, доцент кафедры социально-культурного сервиса и туризма Института спорта, туризма и сервиса</p><p>Челябинск</p><p>SPIN-код: 4628-6920, AuthorID: 653865</p></bio><bio xml:lang="en"/><email xlink:type="simple">menshikow@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава РФ</institution></aff><aff xml:lang="en"><institution>South-Ural State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО “Южно-Уральский государственный университет (национальный исследовательский университет)”</institution></aff><aff xml:lang="en"><institution>South-Ural State University (national research university)</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>01</day><month>03</month><year>2019</year></pub-date><volume>18</volume><issue>1</issue><fpage>82</fpage><lpage>89</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Белов В.В., Меньщиков А.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Белов В.В., Меньщиков А.А.</copyright-holder><copyright-holder xml:lang="en">Belov V.V., Menshchikov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/618">https://cardiovascular.elpub.ru/jour/article/view/618</self-uri><abstract><sec><title>Цель</title><p>Цель. Установить связь между функциями 30-летней выживаемости и концентрацией холестерина липопротеинов высокой плотности (ХС ЛВП) у мужчин 40-59 лет, перенесших инфаркт миокарда (ИМ) и на основе полученных результатов определить оптимальный уровень ХС ЛВП для указанного контингента лиц.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включены пациенты (n=141), перенесшие ИМ &gt;6 мес. тому назад и наблюдавшиеся в поликлиниках Металлургического района г. Челябинска по III группе диспансерного учета. Перенесенный ИМ соответствовал типам 1, 2 Третьего универсального определения ИМ. Начальный этап исследования выборки мужчин, которые перенесли ИМ, продолжался с 03.06.1974 до 24.11.1975г. Отрезными точками наблюдения были 0 и 30 лет. Конечной точкой являлся факт смерти. Сведения об умерших устанавливали в ходе ежегодного мониторинга статуса жизни. За период наблюдения скончались 130 чел. (92,2%). Оценка выживаемости проводилась по методу Каплана-Майера, на основе которой построена регрессионная модель Кокса с включением в нее последовательно повышающихся от минимального значения уровня ХС ЛВП, чтобы кривые выживаемости оказались достоверно различающимися. Определяли 95% доверительные интервалы. Доверительные полосы функции выживаемости строились на основе непараметрического критерия Колмогорова-Смирнова.</p></sec><sec><title>Результаты</title><p>Результаты. Анализ функции 30-летней выживаемости у мужчин 40-59 лет, перенесших ИМ, в зависимости от уровня ХС ЛВП показал наличие статистически значимой зависимости между выживаемостью и уровнями ХС ЛВП. Оптимальными концентрациями ХС ЛВП для выживаемости оказались значения ХС ЛВП ≥2,0 ммоль/л. Показаны статистически значимые периоды различий выживаемости на кривых дожития при различных уровнях ХС ЛВП. Установлена возможность прогнозирования дожития до определенных времен каждого пациента в зависимости от уровня ХС ЛВП. Исходные уровни ХС ЛВП определяют начало, длительность, окончание периодов статистически значимых различий выживаемости на кривых дожития.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To establish connection between the functions of 30-year survival rate and concentration of cholesterol high density lipoproteins (C-HDL) in men aged 40-59 years with a past history of a myocardial infarction (MI) and relying on the obtained data to determine the optimal level of C-HDL for the specified cohort.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study includes 141 patients who have had MI more than 6 months ago and observed in clinics of Metallurgical district of the city of Chelyabinsk within the third group of dispensary register. Specified MI cases refer to types 1, 2 of the Third universal definition of MI. The initial stage of study of the target group of men who have a past history of MI lasted from 03.06.1974 to 24.11.1975. Observation points were 0 and 30 years. The endpoint was death. Information about the dead established during the annual monitoring of the status of life. During the observation period 130 persons/92,2% died. Evaluation of survival was carried out according to the method of Kaplan-Meier, based on which a Cox regression model was built with the inclusion of successively higher minimum level of C-HDL, so that survival curves were significantly different. 95% confidence intervals were determined. The confidence bands of survival functions were built on the basis of on non-parametric Kolmogorov-Smirnov test.</p></sec><sec><title>Results</title><p>Results. The analysis of the function of 30-year survival in men aged 40-59 with past history of MI, depending on the level of HDL-C showed: the presence of statistically significant relationships between survival and levels of HDL-C. Optimal concentrations of HDL cholesterol for survival were the values of HDL-C ≥2,0 mmol/l. Statistically significant periods of survival differences are shown on survival curves at different levels of HDL-C. The possibility of prediction of survival of each patient to a certain time depending on the level HDL-C is determined. Initial levels of HDL-C determine the beginning, duration, end of periods of statistically significant survival differences on survival curves.</p></sec><sec><title>Conclusion</title><p>Conclusion. The analysis of 30-year monitoring of the life status of cohort of men aged 40-59 with past history of MI showed a statistically significant dependence of survival on the initial level of HDL-C. The initial concentration of HDL-C are optimal for survival of indicated cohorts of men. HDL-C levels of 2,0-2,9 mmol/l can serve as a therapeutic target for men aged 40-59 with a past history of MI. The functions of 30-year survival in the cohort of middle-aged men who underwent MI, allow to determine the probability of survival of patients with this level of HDL-C to certain time.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>целевые уровни холестерина липопротеидов высокой плотности</kwd><kwd>30-летнее когортное исследование</kwd><kwd>мужчины 40-59 лет с перенесенным инфарктом миокарда</kwd><kwd>выживаемость</kwd><kwd>мониторинг жизни</kwd></kwd-group><kwd-group xml:lang="en"><kwd>target C-HDL levels</kwd><kwd>30-year cohort prospective study</kwd><kwd>men aged 40-59 with past history of MI</kwd><kwd>survival</kwd><kwd>life monitoring</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">ФГАОУ ВО «Южно-Уральский государственный  университет (национальный исследовательский университет)»; ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава РФ</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Matthew N, Ramachandran SV. Recent Update to the US Cholesterol Treatment Guidelines: A Comparison with International Guidelines. Circulation. 2016;133(18):1795-806. doi:10.1161/CIRCULATIONAHA.116.021407.</mixed-citation><mixed-citation xml:lang="en">Matthew N, Ramachandran SV. Recent Update to the US Cholesterol Treatment Guidelines: A Comparison with International Guidelines. Circulation. 2016;133(18):1795-806. doi:10.1161/CIRCULATIONAHA.116.021407.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9:617-70. doi:10.2147/VHRM.S37119.</mixed-citation><mixed-citation xml:lang="en">Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9:617-70. doi:10.2147/VHRM.S37119.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lin GM, Li YH, Lin CL, et al. Low high-density lipoprotein cholesterol and low/ normal body mass index are associated with increased mortality in coronary artery disease patients in Taiwan. Circ J. 2013;77(8):2079-87. doi:10.1253/circj.CJ-12-1511.</mixed-citation><mixed-citation xml:lang="en">Lin GM, Li YH, Lin CL, et al. Low high-density lipoprotein cholesterol and low/ normal body mass index are associated with increased mortality in coronary artery disease patients in Taiwan. Circ J. 2013;77(8):2079-87. doi:10.1253/circj.CJ-12-1511.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Di Angelantonio E, Gao P, Pennells L, et al.; Emerging Risk Factors Collaboration. Lipidrelated markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499- 506. doi:10.1001/jama.2012.6571.</mixed-citation><mixed-citation xml:lang="en">Di Angelantonio E, Gao P, Pennells L, et al.; Emerging Risk Factors Collaboration. Lipidrelated markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499- 506. doi:10.1001/jama.2012.6571.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ge P, Dong C, Ren X, et al. The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. PLoS One. 2015;10(12):e0144104. doi:10.1371/journal.pone.0144104.</mixed-citation><mixed-citation xml:lang="en">Ge P, Dong C, Ren X, et al. The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. PLoS One. 2015;10(12):e0144104. doi:10.1371/journal.pone.0144104.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Alpert JS, Jaffe AS, et al. The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/ American Heart Association (AHA)/World Heart Federation (WHF). Task Force for the Universal Definition of Myocardial Infarction. JACC. 2018;72(18):2231-64. doi:10.1016/j.jacc.2018.08.1038.</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Alpert JS, Jaffe AS, et al. The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/ American Heart Association (AHA)/World Heart Federation (WHF). Task Force for the Universal Definition of Myocardial Infarction. JACC. 2018;72(18):2231-64. doi:10.1016/j.jacc.2018.08.1038.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Оганов Р. Г., Бойцов С. А. Редакционная с. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.</mixed-citation><mixed-citation xml:lang="en">Oganov RG, Boytsov SA. Editorial a. Cardiovascular prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Белов В. В., Меньщиков А. А. Выживаемость когорт пациентов кардиологического профиля и здоровых мужчин в возрасте 40-59 лет (данные 30-летнего наблюдения). Кардиоваскулярная терапия и профилактика. 2013;12(2):74-9. doi: 10.15829/1728-8800-2013-2-74-79.</mixed-citation><mixed-citation xml:lang="en">Belov VV, Menshchikov AA. Survival of cogorts of cardiac patients and healthy men aged 40-59 years: the 30-year follow-up data. Cardiovascular Therapy and Prevention. 2013;12(2):74-9. (In Russ.) doi: 10.15829/1728-8800-2013-2-74-79.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hirata A, Okamura T, Sugiyama D, et al. NIPPON DATA90 Research Group. The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population. J Atheroscler Thromb. 2016;23(7):800-9. doi:10.5551/jat.33449.</mixed-citation><mixed-citation xml:lang="en">Hirata A, Okamura T, Sugiyama D, et al. NIPPON DATA90 Research Group. The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population. J Atheroscler Thromb. 2016;23(7):800-9. doi:10.5551/jat.33449.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation. 2013;128(10):1112- 21. doi:10.1161/CIRCULATIONAHA.113.002683.</mixed-citation><mixed-citation xml:lang="en">Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation. 2013;128(10):1112- 21. doi:10.1161/CIRCULATIONAHA.113.002683.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Klempfner R, Erez A, Sagit BZ, et al. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016; 9(2):100-8. doi:10.1161/CIRCOUTCOMES.115.002104.</mixed-citation><mixed-citation xml:lang="en">Klempfner R, Erez A, Sagit BZ, et al. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016; 9(2):100-8. doi:10.1161/CIRCOUTCOMES.115.002104.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(5):484-525. doi:10.1016/j.jacl.2013.08.001.</mixed-citation><mixed-citation xml:lang="en">Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(5):484-525. doi:10.1016/j.jacl.2013.08.001.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed HM, Miller M, Nasir K, et al. Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2016;183(10): 875-83. doi:10.1093/aje/kwv305.</mixed-citation><mixed-citation xml:lang="en">Ahmed HM, Miller M, Nasir K, et al. Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2016;183(10): 875-83. doi:10.1093/aje/kwv305.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sharif S, van der Graaf Y, Nathoe H M et al. SMART Study Group. HDL cholesterol as a residual risk factor for vascular events end all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2016;39:1424-30. doi:10.2337/dc16-0155.</mixed-citation><mixed-citation xml:lang="en">Sharif S, van der Graaf Y, Nathoe H M et al. SMART Study Group. HDL cholesterol as a residual risk factor for vascular events end all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2016;39:1424-30. doi:10.2337/dc16-0155.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
